OWL Metabolomics

ProSciento, OWL Metabolomics partner on NAFLD/NASH trial recruitment

Monday, June 12, 2017

ProSciento, a full scope clinical R&D services provider focused exclusively on metabolic diseases, and OWL Metabolomics, a biotechnology company pioneering virtual biopsy assays for the diagnosis of NAFLD/NASH, announced an exclusive, multi-year collaboration aimed at identifying individuals who are eligible for enrollment into clinical trials of therapeutic candidates to treat NAFLD (non-alcoholic fatty liver disease) and NASH (steatohepatitis).

[Read More]